Addex Pharmaceuticals (SWISS: ADXN) announced that based on preliminary review of the unblinded data from study 206, it has terminated development of ADX10059 for chronic indications, including long term treatment of gastroesophageal reflux disease and migraine prophylaxis.

“Screening for Barrett’s esophagus in asymptomatic women”
Barrett’s esophagus is a condition where the lining of the esophagus changes due to chronic inflammation, generally from gastroesophageal reflux disease (GERD). Barrett’s esophagus is important to recognize as it may increase the risk of developing esophageal cancer. It has been detected in approximately 10 percent of patients with [...]

Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study.

Every day, more than 20 percent of the U.S. population experiences the painful burning symptoms of gastroesophageal reflux disease (GERD). For these 20 million Americans, the first line of defense is medication. To find a long-term, permanent solution for this nagging condition, the Center for the Future of Surgery at UC San Diego Medical Center [...]

New Mayo Clinic research has found that survival rates of patients with Barrett’s esophagus, which can be a precursor for esophageal cancer, are no different than the survival rates for the general population.